Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 20 Jan 2010 |
| ORION CORPORATION: Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2010 AGM of Orion Corporation, 19 Jan 2010 | 19 Jan 2010 |
| 200,000 Orion A-shares converted into B-shares | 4 Jan 2010 |
| Orion clarifies information emanating from Capital Markets Day | 4 Dec 2009 |
| 100,000 Orion A-shares converted into B-shares | 27 Nov 2009 |